These findings provide proof-of-principle that targeting TRiC, or more specifically targeting the interaction between TRiC and Stat3, may provide a novel approach to reducing levels of activated Stat3 for therapeutic benefit in cancer. The gene discussed is STAT3; the disease is cancer.